Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 11/20 | 0.86 |
| ▸ | PTK2B | Q14289 | 10/20 | 0.69 |
| ▸ | BCL6 | P41182 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | INSR | P06213 | 3/20 | 0.47 |
| ▸ | PLK1 | P53350 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211830 | 0.93 | PTK2 (1.00) | PTK2PTK2BBCL6KDRINSR | |
| SCHEMBL6210578 | 0.89 | PTK2 (0.86) | PTK2PTK2BBCL6KDRINSR | |
| SCHEMBL6211907 | 0.88 | PTK2 (0.67) | PTK2PTK2BBCL6KDRINSR | |
| SCHEMBL6214304 | 0.87 | PTK2 (0.87) | PTK2PTK2BBCL6KDRINSR | |
| SCHEMBL6216003 | 0.87 | PTK2 (0.87) | PTK2PTK2BBCL6KDRINSR | |
| SCHEMBL6213071 | 0.85 | PTK2 (0.64) | PTK2PTK2BBCL6KDRINSR | |
| SCHEMBL6209866 | 0.85 | PTK2 (0.63) | PTK2PTK2BBCL6KDRINSR | |
| SCHEMBL6211093 | 0.84 | PTK2 (0.84) | PTK2PTK2BBCL6KDRINSR | |
| SCHEMBL6211591 | 0.82 | PTK2B (0.61) | PTK2PTK2BBCL6KDRINSR | |
| SCHEMBL6209931 | 0.82 | PTK2 (0.77) | PTK2PTK2BBCL6KDRINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | claimed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | CCNA1, CCNB1, CCNT1 | PTK2 3004/4885PTK2B 1941/4885BCL6 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.